Skip to main content
Premium Trial:

Request an Annual Quote

Lineagen Raises $5M, Closes Series A Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic diagnostics development firm Lineagen today announced it has raised $5 million bringing the total for its Series A financing round to $10.8 million.

The company, which raised $5.8 million in the first close of the round in 2007, will use the funds to further develop Lineagen's lead autism program and support its planned commercial service launch in September, it said in a statement.

Participants in the most recent tranche include new investor PrairieGold Venture Partners and existing partners Sanderling Ventures, vSpring Capital, and Mesa Verde Venture Partners.

Mike Jerstad, a partner in PrairieGold, will join the board of Lineagen, which is based in Salt Lake City.

The company is developing genomic tests and services for "complex" diseases, such as autism, multiple sclerosis, and COPD.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.